Pink Sheet Regulation https://pink.pharmaintelligence.informa.com/search#?&sortBy=date&sortOrder=desc&publication=Pink%20Sheet&subjects=Regulation Search RSS en-us 2017 webpubs@informa.com https://users.feedblitz.com/af3be2ad55fb9d5e948afcd347c6c76e/pink_logo.png Pink Sheet Regulation https://pink.pharmaintelligence.informa.com/search#?&sortBy=date&sortOrder=desc&publication=Pink%20Sheet&subjects=Regulation https://pink.pharmaintelligence.informa.com/PS144475/Coronavirus%20Notebook%20EMA%20OKs%20More%20Vaccine%20Production%20Plants%20WHO%20Sounds%20Alert%20Over%20Africa?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144475/Coronavirus Notebook EMA OKs More Vaccine Production Plants WHO Sounds Alert Over Africa https://pink.pharmaintelligence.informa.com/PS144475/Coronavirus%20Notebook%20EMA%20OKs%20More%20Vaccine%20Production%20Plants%20WHO%20Sounds%20Alert%20Over%20Africa?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News Coronavirus Notebook: EMA OKs More Vaccine Production Plants, WHO Sounds Alert Over Africa ]]> 2021-06-14T09:07:42-04:00 The EU has OKd more manufacturing capacity for the Moderna COVID-19 vaccine Source: Alamy PS144475 Mon, 14 Jun 2021 09:07:42 GMT Ian Schofield ian.schofield@informa.com Coronavirus COVID-19 Vaccines Safety Distribution Middle East and Africa International Europe United Kingdom Regulation Infectious Diseases BioPharmaceutical 0Vaxzevria should not be given to people who have had capillary leak syndrome, the EU regulator says. The G7 leaders...

]]> https://pink.pharmaintelligence.informa.com/PS144474/New%20EU%20Filings?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144474/New EU Filings https://pink.pharmaintelligence.informa.com/PS144474/New%20EU%20Filings?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News New EU Filings      

Related Stories

 ]]> 2021-06-14T07:20:45-04:00 PS144474 Mon, 14 Jun 2021 07:20:45 GMT Neena Brizmohun neena.brizmohun@informa.com Europe Drug Review Review Pathway Regulation Approvals Market Access European Performance Tracker BioPharmaceutical 0Janssen/Legend Biotech's ciltacabtagene autoleucel and Ipsen's palovarotene are among the latest new medicines that have been submitted for pan-EU approval.

]]> https://pink.pharmaintelligence.informa.com/PS144473/Keeping%20Track%20US%20FDA%20Clears%20Pfizers%20Prevnar%2020%20Dermavant%20Submits%20Tapinirof%20Adamis%20Returns%20With%20Zimhi?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144473/Keeping Track US FDA Clears Pfizers Prevnar 20 Dermavant Submits Tapinirof Adamis Returns With Zimhi https://pink.pharmaintelligence.informa.com/PS144473/Keeping%20Track%20US%20FDA%20Clears%20Pfizers%20Prevnar%2020%20Dermavant%20Submits%20Tapinirof%20Adamis%20Returns%20With%20Zimhi?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News Keeping Track: US FDA Clears Pfizer’s Prevnar 20; Dermavant Submits Tapinirof, Adamis Returns With Zimhi ]]> 2021-06-11T23:59:00-04:00 PS144473 Fri, 11 Jun 2021 23:59:00 GMT Bridget Silverman bridget.silverman@informa.com US FDA Performance Tracker Drug Approval Standards Approvals Vaccines Infectious Diseases Regulation BioPharmaceutical United States 5The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

]]> https://pink.pharmaintelligence.informa.com/PS144464/Pazdurs%20Post-Mortem%20On%20Dangling%20Accelerated%20Approvals%20Message%20At%20ODAC%20Was%20Heard%20Loud%20And%20Clear?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144464/Pazdurs Post-Mortem On Dangling Accelerated Approvals Message At ODAC Was Heard Loud And Clear https://pink.pharmaintelligence.informa.com/PS144464/Pazdurs%20Post-Mortem%20On%20Dangling%20Accelerated%20Approvals%20Message%20At%20ODAC%20Was%20Heard%20Loud%20And%20Clear?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss Analysis Pazdur’s Post-Mortem On ‘Dangling’ Accelerated Approvals: Message At ODAC Was Heard Loud And Clear ]]> 2021-06-11T23:58:00-04:00 Source: Alamy PS144464 Fri, 11 Jun 2021 23:58:00 GMT Kate Rawson kate@previsionpolicy.com Review Pathway Cancer Regulation BioPharmaceutical Advisory Committees United States 25The three-day advisory committee was intended to ‘put companies on notice’ about the importance of confirmatory trials. The result? Mission...

]]> https://pink.pharmaintelligence.informa.com/PS144471/Aduhelm%20Approval%20Firestorm%20Raises%20Question%20What%20Are%20US%20FDA%20Advisory%20Committees%20For%20Anyway?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144471/Aduhelm Approval Firestorm Raises Question What Are US FDA Advisory Committees For Anyway https://pink.pharmaintelligence.informa.com/PS144471/Aduhelm%20Approval%20Firestorm%20Raises%20Question%20What%20Are%20US%20FDA%20Advisory%20Committees%20For%20Anyway?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss Analysis Aduhelm Approval Firestorm Raises Question: What Are US FDA Advisory Committees For, Anyway? ]]> 2021-06-11T14:34:00-04:00 US FDA approval of Alzheimer's disease drug Aduhelm riles advisory panel Source: photo illustration/Alamy images PS144471 Fri, 11 Jun 2021 14:34:00 GMT Brenda Sandburg Brenda.Sandburg@informa.com Advisory Committees Drug Approval Standards Regulation Approvals FDA BioPharmaceutical United States Neurology 35After three panel members resign over agency’s approval of Biogen’s Alzheimer’s disease drug, the ‘billion-dollar question’ is why FDA provided...

]]> https://pink.pharmaintelligence.informa.com/PS144468/COVID-19%20Vaccines%20Myocarditis%20Reports%20Could%20Slow%20Expansion%20Into%20Pediatric%20Age%20Groups?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144468/COVID-19 Vaccines Myocarditis Reports Could Slow Expansion Into Pediatric Age Groups https://pink.pharmaintelligence.informa.com/PS144468/COVID-19%20Vaccines%20Myocarditis%20Reports%20Could%20Slow%20Expansion%20Into%20Pediatric%20Age%20Groups?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News COVID-19 Vaccines: Myocarditis Reports Could Slow Expansion Into Pediatric Age Groups ]]> 2021-06-11T13:55:00-04:00 One FDA panelist worries the reports of myocarditis following mRNA vaccination are just the tip of the iceberg. Source: Alamy PS144468 Fri, 11 Jun 2021 13:55:00 GMT Sue Sutter sue.sutter@informa.com Vaccines Coronavirus COVID-19 Advisory Committees Pediatrics Drug Safety Regulation Infectious Diseases BioPharmaceutical United States 40Concerns about cases of heart muscle inflammation occurring in older male adolescents and young men shortly after the second dose...

]]> https://pink.pharmaintelligence.informa.com/PS144467/Interpol-Led%20Campaign%20Seizes%20Nine%20Million%20Falsified%20Medical%20Products?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144467/Interpol-Led Campaign Seizes Nine Million Falsified Medical Products https://pink.pharmaintelligence.informa.com/PS144467/Interpol-Led%20Campaign%20Seizes%20Nine%20Million%20Falsified%20Medical%20Products?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News Interpol-Led Campaign Seizes Nine Million Falsified Medical Products ]]> 2021-06-11T11:23:35-04:00 Counterfeiters are taking advantage of the pandemic Source: Alamy PS144467 Fri, 11 Jun 2021 11:23:35 GMT Ian Schofield ian.schofield@informa.com Europe Switzerland United Kingdom International Enforcement Quality Regulation BioPharmaceutical Coronavirus COVID-19 Infectious Diseases 10This year’s Pangea operation has led to the seizure of millions of falsified medicines and other products and the closure...

]]> https://pink.pharmaintelligence.informa.com/PS144466/Roches%20Novel%20Ranibizumab%20Implant%20Among%20Myriad%20New%20Filings%20In%20EU?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144466/Roches Novel Ranibizumab Implant Among Myriad New Filings In EU https://pink.pharmaintelligence.informa.com/PS144466/Roches%20Novel%20Ranibizumab%20Implant%20Among%20Myriad%20New%20Filings%20In%20EU?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News Roche’s Novel Ranibizumab Implant Among Myriad New Filings In EU ]]> 2021-06-11T11:07:09-04:00 Age-related macular degeneration usually first affects people in their 50s and 60s Source: Alamy PS144466 Fri, 11 Jun 2021 11:07:09 GMT Neena Brizmohun neena.brizmohun@informa.com Drug Review Europe Approvals Drug Delivery Market Access Regulation Review Pathway Cancer Ophthalmic Orthopedics Neurology BioPharmaceutical 15The European Medicines Agency has added 13 new drugs to its list of products that are under review for potential...

]]> https://pink.pharmaintelligence.informa.com/PS144465/China%20Reg%20Express%20AntiBlocking%20Law%20Inspection%20Guideline%20And%20Gene%20Therapy%20FollowUp%20Studies?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144465/China Reg Express AntiBlocking Law Inspection Guideline And Gene Therapy FollowUp Studies https://pink.pharmaintelligence.informa.com/PS144465/China%20Reg%20Express%20AntiBlocking%20Law%20Inspection%20Guideline%20And%20Gene%20Therapy%20FollowUp%20Studies?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News China Reg Express: Anti-Blocking Law, Inspection Guideline And Gene Therapy Follow-Up Studies ]]> 2021-06-11T04:39:53-04:00 CHINA ISSUES ANTI-BLOCKING LAW, AMONG OTHER REGULATIONS Source: Alamy PS144465 Fri, 11 Jun 2021 04:39:53 GMT Brian Yang brian.yang@informa.com China Legislation Regulation Gene Therapy BioPharmaceutical 18A sweeping "anti-blocking" law, patent legislation, gene therapy study guidance and new regulations on inspections are all within a flurry...

]]> https://pink.pharmaintelligence.informa.com/PS144458/COVID19%20IP%20Waiver%20Breakthrough%20At%20WTO%20Meeting?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144458/COVID19 IP Waiver Breakthrough At WTO Meeting https://pink.pharmaintelligence.informa.com/PS144458/COVID19%20IP%20Waiver%20Breakthrough%20At%20WTO%20Meeting?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News COVID-19 IP Waiver 'Breakthrough' At WTO Meeting ]]> 2021-06-11T04:03:44-04:00 WTO Members Debate Whether IP Is A Barrier To COVID-19 Vaccines And Treatments Source: Alamy PS144458 Fri, 11 Jun 2021 04:03:44 GMT Francesca Bruce Francesca.bruce@informa.com International Europe Coronavirus COVID-19 Intellectual Property Legal Issues Policy Regulation Vaccines BioPharmaceutical 25Health advocates hail the move but the EU and UK still insist a waiver is not the solution to boosting...

]]> https://pink.pharmaintelligence.informa.com/PS144462/Aduhelm%20Approval%20Raises%20Concerns%20About%20US%20FDA%20Leadership%20Senate%20Finance%20Chair%20Suggests?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144462/Aduhelm Approval Raises Concerns About US FDA Leadership Senate Finance Chair Suggests https://pink.pharmaintelligence.informa.com/PS144462/Aduhelm%20Approval%20Raises%20Concerns%20About%20US%20FDA%20Leadership%20Senate%20Finance%20Chair%20Suggests?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News Aduhelm Approval Raises Concerns About US FDA Leadership, Senate Finance Chair Suggests ]]> 2021-06-10T23:54:00-04:00 Sen. Ron Wyden, D-OR, Points To Janet Woodcock's Responsibility For Approval Based On 'Skimpy' Evidence Source: screenshot PS144462 Thu, 10 Jun 2021 23:54:00 GMT Cathy Kelly Catherine.Kelly@informa.com FDA Pricing Debate Regulation Reimbursement Medicare Approvals Policy BioPharmaceutical United States 35Ron Wyden points to expectations Biogen’s drug will impose a heavy cost burden on Medicare as he questions FDA’s decision...

]]> https://pink.pharmaintelligence.informa.com/PS144460/Alzheimers%20Can%20Follow%20HIV%20And%20Become%20Chronic%20Condition%20If%20Science%20Advances%20Woodcock%20Argues?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144460/Alzheimers Can Follow HIV And Become Chronic Condition If Science Advances Woodcock Argues https://pink.pharmaintelligence.informa.com/PS144460/Alzheimers%20Can%20Follow%20HIV%20And%20Become%20Chronic%20Condition%20If%20Science%20Advances%20Woodcock%20Argues?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss Analysis Alzheimer’s Can Follow HIV And Become Chronic Condition If Science Advances, Woodcock Argues ]]> 2021-06-10T23:42:15-04:00 Acting FDA Commissioner Janet Woodcock answers questions during a Senate appropriations subcommittee hearing. Source: Screenshot PS144460 Thu, 10 Jun 2021 23:42:15 GMT Derrick Gingery derrick.gingery@informa.com Neurology Research and Development Strategies Regulation FDA BioPharmaceutical United States 10The acting US FDA commissioner equates drug development in the neurodegenerative diseases to work on HIV.

]]> https://pink.pharmaintelligence.informa.com/PS144457/US%20Survey%20Shows%20Pharma%20More%20Open%20To%20Remote%20Patient%20Monitoring?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144457/US Survey Shows Pharma More Open To Remote Patient Monitoring https://pink.pharmaintelligence.informa.com/PS144457/US%20Survey%20Shows%20Pharma%20More%20Open%20To%20Remote%20Patient%20Monitoring?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News US Survey Shows Pharma More Open To Remote Patient Monitoring ]]> 2021-06-10T11:38:59-04:00 Heart Rate Is Among Most Important Parameters Tracked In Clinical Trials Source: Alamy PS144457 Thu, 10 Jun 2021 11:38:59 GMT Vibha Sharma vibha.sharma@informa.com United States Clinical Trials Coronavirus COVID-19 Regulation BioPharmaceutical 15COVID-19 is driving changes to how clinical trials are being conducted in the US, with 44% of respondents who participated...

]]> https://pink.pharmaintelligence.informa.com/PS144456/More%20Pressure%20On%20COVID-19%20Product%20Protections%20As%20Euro%20Parliament%20Backs%20IP%20Waiver?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144456/More Pressure On COVID-19 Product Protections As Euro Parliament Backs IP Waiver https://pink.pharmaintelligence.informa.com/PS144456/More%20Pressure%20On%20COVID-19%20Product%20Protections%20As%20Euro%20Parliament%20Backs%20IP%20Waiver?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News More Pressure On COVID-19 Product Protections As Euro Parliament Backs IP Waiver ]]> 2021-06-10T11:28:12-04:00 The G7 summit is taking place in Carbis Bay, Cornwall, UK Source: Alamy PS144456 Thu, 10 Jun 2021 11:28:12 GMT Ian Schofield ian.schofield@informa.com Europe United Kingdom International Coronavirus COVID-19 Vaccines Distribution Intellectual Property Regulation Infectious Diseases BioPharmaceutical 5Expectations will be high after the COVID-19 product IP waiver plan took a big step forward and G7 leaders prepare...

]]> https://pink.pharmaintelligence.informa.com/PS144449/Combined%20Trial%20Reviews%20To%20Become%20The%20Norm%20In%20UK%20From%202022?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144449/Combined Trial Reviews To Become The Norm In UK From 2022 https://pink.pharmaintelligence.informa.com/PS144449/Combined%20Trial%20Reviews%20To%20Become%20The%20Norm%20In%20UK%20From%202022?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News Combined Trial Reviews To Become The Norm In UK From 2022 ]]> 2021-06-10T04:26:40-04:00 UK Is Streamlining The Way Clinical Trials Are Reviewed Source: Shutterstock PS144449 Thu, 10 Jun 2021 04:26:40 GMT Vibha Sharma vibha.sharma@informa.com United Kingdom Clinical Trials Regulation BioPharmaceutical 25Having gained enough experience with the combined ethics and regulatory review of clinical trial applications, the UK will make this...

]]> https://pink.pharmaintelligence.informa.com/PS144455/Pazdurcanumab%20US%20FDAs%20Top%20Cancer%20Official%20Weighs%20In%20On%20That%20Big%20Neurology%20Approval?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144455/Pazdurcanumab US FDAs Top Cancer Official Weighs In On That Big Neurology Approval https://pink.pharmaintelligence.informa.com/PS144455/Pazdurcanumab%20US%20FDAs%20Top%20Cancer%20Official%20Weighs%20In%20On%20That%20Big%20Neurology%20Approval?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss Opinion Pazdurcanumab: US FDA’s Top Cancer Official Weighs In On That Big Neurology Approval
      
]]> 2021-06-09T22:00:09-04:00 OCE Director Richard Pazdur is part of the US FDA's brain trust on accelerated approval Source: photo illustration/Alamy, FDA PS144455 Wed, 09 Jun 2021 22:00:09 GMT Kate Rawson kate@previsionpolicy.com Drug Approval Standards Review Pathway Neurology Regulation Cancer BioPharmaceutical United States 40Richard Pazdur is eager for a conversation about how to improve the Accelerated Approval pathway. The OCE director welcomes aducanumab’s...

      
]]> https://pink.pharmaintelligence.informa.com/PS144453/BsUFA%20III%20Negotiations%20Nearly%20Done%20Commitment%20Letter%20Being%20Written?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144453/BsUFA III Negotiations Nearly Done Commitment Letter Being Written https://pink.pharmaintelligence.informa.com/PS144453/BsUFA%20III%20Negotiations%20Nearly%20Done%20Commitment%20Letter%20Being%20Written?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss Analysis BsUFA III Negotiations Nearly Done; Commitment Letter Being Written ]]> 2021-06-09T20:48:45-04:00 When BsUFA III talks end, only the generic drug user fee reauthorization negotiations will remain ongoing. Source: Alamy PS144453 Wed, 09 Jun 2021 20:48:45 GMT Derrick Gingery derrick.gingery@informa.com Biosimilars User Fees Review Pathway Regulation BioPharmaceutical United States 5Supplement approval timeline and regulatory science issues apparently have been resolved.

]]> https://pink.pharmaintelligence.informa.com/PS144452/Cancer%20Trials%20PatientReported%20Outcomes%20Should%20Measure%20Five%20Core%20Concepts%20US%20FDA%20Says?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144452/Cancer Trials PatientReported Outcomes Should Measure Five Core Concepts US FDA Says https://pink.pharmaintelligence.informa.com/PS144452/Cancer%20Trials%20PatientReported%20Outcomes%20Should%20Measure%20Five%20Core%20Concepts%20US%20FDA%20Says?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News Cancer Trials: Patient-Reported Outcomes Should Measure Five Core Concepts, US FDA Says ]]> 2021-06-09T20:17:52-04:00 US FDA has suggested a set of core concepts on which it would like to see PRO data from cancer registrational trials. Source: Alamy PS144452 Wed, 09 Jun 2021 20:17:52 GMT Sue Sutter sue.sutter@informa.com Clinical Trials Guidance Documents Cancer Regulation BioPharmaceutical United States 35Heterogeneity in PRO assessment strategies has lessened the regulatory utility of such data from cancer trials, the agency says; new...

]]> https://pink.pharmaintelligence.informa.com/PS144448/New%20COVID-19%20Vaccine%20Patent%20Database%20Launched?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144448/New COVID-19 Vaccine Patent Database Launched https://pink.pharmaintelligence.informa.com/PS144448/New%20COVID-19%20Vaccine%20Patent%20Database%20Launched?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss News New COVID-19 Vaccine Patent Database Launched ]]> 2021-06-09T12:29:13-04:00 A new resource for COVID-19 vaccine patents is now available Source: Alamy PS144448 Wed, 09 Jun 2021 12:29:13 GMT Ian Schofield ian.schofield@informa.com International Coronavirus COVID-19 Vaccines Intellectual Property Infectious Diseases BioPharmaceutical Regulation 15As part of its drive to maximize global access to coronavirus vaccines, the Medicines Patent Pool has developed a publicly...

]]> https://pink.pharmaintelligence.informa.com/PS144440/UK%20Branded%20Medicines%20Pricing%20%20Access%20Deal%20%20Hits%20%20Misses%20To%20Date?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss https://pink.pharmaintelligence.informa.com/PS144440/UK Branded Medicines Pricing Access Deal Hits Misses To Date https://pink.pharmaintelligence.informa.com/PS144440/UK%20Branded%20Medicines%20Pricing%20%20Access%20Deal%20%20Hits%20%20Misses%20To%20Date?utm_source=search&utm_medium=RSS&utm_term=&utm_campaign=search_rss Analysis UK Branded Medicines Pricing & Access Deal - Hits & Misses To Date ]]> 2021-06-09T08:57:49-04:00 Drug pricing is rarely off the radar Source: ALAMY PS144440 Wed, 09 Jun 2021 08:57:49 GMT Leela Barham United Kingdom Market Access Reimbursement Pricing Strategies Health Technology Assessment Policy Regulation BioPharmaceutical 30Industry has paid millions of pounds under the ongoing UK Voluntary Scheme on Branded Medicines Pricing and Access but there...

]]>